Lupus (SLE): vizsgálatok itt: Kína
163 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Where
- Beijing, Changchun, Chengdu, Guangzhou, Linyi, Nanchang, Nanjing, Ningbo, Pingxiang, Shanghai, Shantou, Suzhou, Ürümqi, Wenzhou, Xinxiang
- Életkor
- 12 év to 100 év
- People
- 550 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00 - 3. fázisTaking peoplePhase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
- Where
- Beijing, Binzhou, Changchun, Chongqing, Guangzhou, Liuzhou, Ningbo, Shanghai, Shantou, Shenyang, Shenzhen, Wuhan
- Életkor
- 18 év to 100 év
- People
- 348 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00 - 1. fázisTaking peopleTo Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- Where
- Beijing, Pingxiang
- Életkor
- 18 év to 75 év
- People
- 46 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- Ganzhou, Guangzhou
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Where
- Baotou, Changchun, Chengdu, Fuzhou, Guangzhou, Jinan, Luoyang, Nanjing, Shijiazhuang, Suzhou
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00 - No phaseNot yet taking people in KínaMYTP01 for Immune-Mediated Diseases
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 160
- Run by
- Zhejiang Provincial People's Hospital
See details and how to joinNCT07901764 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua, Jining, Linfen, Luoyang, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shanwei, Suzhou, Taiyuan, Wenzhou, Xinxiang
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Guilin, Haikou, Hangzhou, Jinan, Jiujiang, Nanchang, Nanjing, Nanning, Pingxiang, Shanghai, Shantou, Shijiazhuang, Suzhou, Tianjin, Urumuqi, Wenzhou, Wuhan, Xiamen, Xi'an, Yangzhou, Zhengzhou, Zhuzhou
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - 1. fázisTaking peopleA Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- Where
- Beijing, Luoyang, Shanghai, Wuhan
- Életkor
- 18 év to 75 év
- People
- 21 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00 - 1. fázisTaking peopleStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Where
- Beijing, Chengdu, Nanjing
- Életkor
- 18 év to 65 év
- People
- 48 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00 - 2. fázisTaking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai, Suzhou, Wenzhou
- Életkor
- 18 év to 74 év
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Beijing, Chongqing, Guangzhou, Jinan, Lanzhou, Shanghai, Shenzhen
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 1. fázisTaking peopleA Study of ATG-201 in Adult Participants With Autoimmune Diseases
- Where
- Beijing, Bengbu, Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Luoyang, Nanjing, Shanghai, Suzhou, Taiyuan, Wuhan, Xiamen, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 149
- Run by
- Antengene Biologics Limited
See details and how to joinNCT07732309 - No phaseTaking peopleAn Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06379646 - 3. fázisTaking peopleA Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
- Where
- Beijing, Bengbu, Changchun, Changde, Changlexi, Changsha, Chengdu, Dalian, Fuzhou, Guangdong Province, Guangzhou, Hangzhou, Harbin, Hefei, Hengyang, Hohhot, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Xiamen, Xi'an, Yangzhou, Yantai, Zhengzhou
- Életkor
- 18 év to 70 év
- People
- 417
- Run by
- AstraZeneca
See details and how to joinNCT07751848 - 1. fázisTaking peopleA Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06978647 - 1. fázisTaking peopleA Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07104721 - 1. fázisTaking peopleA Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07123519 - 1. fázisTaking peopleA Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
- Where
- Beijing, Bengbu, Changsha, Chengdu, Guangzhou, Mianyang, Nanjing, Pingxiang, Shanghai, Taiyuan, Xian
- Életkor
- 18 év to 60 év
- People
- 117
- Run by
- Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT07323173 - 1/2. fázisTaking peopleA Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- Where
- Baoji, Beijing, Bengbu, Changsha, Hefei, Mianyang, Nanchang, Suzhou, Taiyuan, Zaozhuang
- Életkor
- 18 év to 65 év
- People
- 30
- Run by
- Climb Bio, Inc.
See details and how to joinNCT07564596 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Beijing, Shanghai, Wuhan, Zhengzhou
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 1. fázisTaking peopleA Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- Therorna
See details and how to joinNCT07413341 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Beijing, Changchun, Guangzhou, Guilin, Shanghai, Shantou, Suzhou, Tianjin, Wenzhou, Wuhan, Yangzhou, Zhengzhou
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 1. fázisTaking peopleA Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Where
- Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
- Életkor
- 18 év to 55 év
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07276958 · EU 2026-527207-25-00 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Beijing, Binzhou, Changchun, Changsha, Dongguan, Guangzhou, Haikou, Jiujiang, Ningbo, Pingxiang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Zhongshan, Zhuzhou
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00